Plain English summary {#Sec1}
=====================

The aim of writing this literature review was to provide the reader with an overview of published studies using the newest version of the Diagnostic and Statistical Manual of Mental Disorders, the DSM-5, in assessing eating disorder prevalence. A literature search was performed in accordance with well established guidelines, resulting in 19 studies fulfilling inclusion criteria. As intended, rates of the residual eating disorder category "other specified feeding and eating disorders" had increased, and preliminary evidence supported increased prevalence of anorexia nervosa, bulimia nervosa and binge eating disorder. No studies assessing the prevalence of feeding disorders (i.e. Pica, Rumination Disorder and Avoidant Restrictive Food Intake Disorders) were identified.

Background {#Sec2}
==========

In 2013, the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) \[[@CR1]\] was replaced by its successor, the DSM-5 \[[@CR2]\], yielding a number of adjustments in diagnostic criteria across psychiatric diagnoses. For eating disorders (ED) in specific, a main intention of the DSM-5 adjustments was to decrease the number of ED cases falling into the former diagnostic category "eating disorder not otherwise specified" (EDNOS), a poorly defined and heterogeneous residual category representing the majority of DSM-IV ED cases. This was done by removing binge eating disorder (BED) from the DSM-IV EDNOS category, and reintroducing it as an independent and specified DSM-5 diagnosis, and by expanding the boundaries of anorexia nervosa (AN) and bulimia nervosa (BN). The DSM-5 retained practically all core AN features, but clarified the weight criteria by changing the wording from "a body weight less than 85% of that expected" to "significantly low weight". Also, the amenorrhea criterion was removed. For BN, the minimum frequency of binge eating episodes and inappropriate compensatory behavior was reduced from twice a week to once a week. In addition to these changes, three disorders previously reserved for children and classified as 'Feeding and Eating Disorders of Infancy or Early Childhood' were revised and introduced in the DSM-5 as independent diagnostic categories: pica, avoidant/restrictive food intake disorder (ARFID) and rumination disorder. Finally, EDNOS was replaced by other specified feeding and eating disorders (OSFED) including atypical AN, subthreshold BN and subthreshold BED, purging disorder (PD), night eating syndrome (NES), as well as unspecified feeding and eating disorders (UFED) representing cases where behaviors cause clinically significant distress/impairment of functioning, but fail to meet full criteria for a feeding or eating disorder.

In the years to come, the new diagnostic criteria for EDs are likely to yield alterations in reported point (proportion of individuals affected by a disorder at the one specific point in time) and lifetime (proportion of individuals having been affected by a disorder at any time in life up to the measurement point) prevalence rates. Historically, ED prevalence rates reported using the DSM-IV have varied considerably across studies, with discrepancies being a result of a number of methodological issues such as inconsistent use of assessment instruments \[[@CR3]\], variations in study designs \[[@CR4]\] and estimates calculated using non-representative samples \[[@CR5]\]. It is therefore important to assess trends in occurrence rates on a regular basis, taking into account changes to diagnostic criteria as well as methodological aspects influencing observed trends.

Following the transition from DSM-IV to DSM-5, it is relevant to review whether the revisions to the DSM-IV have resulted in alterations in diagnostic distribution, and to identify diagnostic categories in need of further research. Four years into the DSM-5 era, a small number of studies do, in fact, show that the new diagnostic system alters the representation and distribution of ED diagnoses with evidence of increased lifetime prevalence of BN and BED \[[@CR6]\] and increased lifetime \[[@CR7]\] and point prevalence \[[@CR8]\] of AN. Further, reduced numbers of identified OSFED and UFED cases \[[@CR9]--[@CR11]\] have also been reported. However, only a limited number of studies have sought to investigate the prevalence of DSM-5 feeding disorders (i.e. pica, ARFID and rumination disorder), or the occurrence of the OSFED categories such as subclinical AN, BN and BED, as well as NES and PD. In sum, there have been important recent developments that warrant further attention. These includes the emergence of new empirical findings from studies assessing ED prevalence using DSM-5 criteria, as well as findings from retrospective studies recoding DSM-IV diagnoses into new DSM-5 ED categories. The aim of this study was to systematically review the field for studies reporting ED prevalence based on DSM-5 criteria in non-clinical female and male samples. The review was performed according to PRISMA guidelines \[[@CR12]\] and synthesized studies published between 2012 and 2017.

Methods {#Sec3}
=======

Search strategy {#Sec4}
---------------

The literature was reviewed in February 2017, using the PubMed search below. The screening process was conducted according to the criteria outlined by the PRISMA guidelines, and is presented in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1The literature screening process according to PRISMA guidelines

(((((((anorexia\[All Fields\] AND nervosa\[All Fields\]) AND DSM-5\[All Fields\] AND prevalence\[All Fields\]) OR ((bulimia\[All Fields\] AND nervosa\[All Fields\]) AND DSM-5\[All Fields\] AND prevalence\[All Fields\])) OR ((binge\[All Fields\] AND eating\[All Fields\] AND disorder\[All Fields\]) AND DSM-5\[All Fields\] AND prevalence\[All Fields\])) OR ((eating\[All Fields\] AND disorder\[All Fields\]) AND DSM-5\[All Fields\] AND prevalence\[All Fields\])) OR (OSFED\[All Fields\] AND DSM-5\[All Fields\] AND prevalence\[All Fields\])) OR (PICA\[All Fields\] AND DSM-5\[All Fields\] AND prevalence\[All Fields\])) OR (avoidant\[All Fields\] AND restrictive\[All Fields\] AND food\[All Fields\] AND intake\[All Fields\] AND disorder\[All Fields\]) AND DSM-5\[All Fields\] AND prevalence\[All Fields\]) OR (rumination\[All Fields\] AND disorder\[All Fields\]) AND DSM-5\[All Fields\] AND prevalence\[All Fields\])

Eligibility criteria {#Sec5}
--------------------

Publications were targeted that examined the epidemiology of EDs, in particular ED prevalence rates, in non-clinical samples, and were selected for review according to the criteria outlined below.A.Articles that presented ED prevalence rates based on DSM-5 criteria (articles presenting recoded diagnostic categories (e.g. from DSM-IV to DSM-5) were also eligible)B.Articles that were written in English or had an available published English translationC.Articles that were published in peer reviewed journals

Exclusion criteria {#Sec6}
------------------

All papers investigating ED prevalence in clinical samples were excluded. Editorials, commentaries, \[systematic\] reviews, as well as articles reporting prevalence of disordered eating without utilizing DSM-5 ED diagnoses (e.g. ED *features* or *syndromes*) were omitted. Exclusions were tracked and registered (see Fig. [1](#Fig1){ref-type="fig"}). Omitted review articles were screened for additional references. No exclusions for age, gender or geographic areas were applied.

Title, abstract and article selection {#Sec7}
-------------------------------------

Publication titles in studies obtained through the search strategy outlined earlier were reviewed by the authors CLD and LW. All titles clearly irrelevant to the aim and scope of the paper (e.g. "Food addiction -- substance use disorder or behavioral addiction") were excluded during this initial screening. Publications with ambiguous titles (e.g. "Eating disorders in older women") and publication with titles clearly relevant to the aim of the paper (e.g. "Prevalence and severity of DSM-5 eating disorders in a community cohort of adolescents") were included at this stage of the screening process. Abstracts were then screened by CLD and LW using a similar strategy (i.e. screening for irrelevance, ambiguity and certainty), after which full texts were retrieved and assessed for eligibility by CLD and LW using the outlined eligibility and exclusion criteria. Agreement was reached for all included and excluded publications. None of the reviewers were blind to the authors of the texts, nor their affiliations.

Results {#Sec8}
=======

Search summary {#Sec9}
--------------

The PubMed search strategy produced 94 titles, which after the initial title screen was reduced to 43. Of these 43, 21 were omitted in the abstract screening process. A total of 22 papers met eligibility criteria and were retained. Subsequently, three full-text studies were excluded based on lack of relevance, leading to a total inclusion of 19 studies. No additional studies were found through the screening of review articles. A more detailed overview of the screening process is presented in Fig. [1](#Fig1){ref-type="fig"} **.**

Table [1](#Tab1){ref-type="table"} summarizes all included studies. No studies meeting eligibility criteria were published before 2012. Assessments of the following full- and subthreshold diagnoses were reported: ED, AN, BN, BED, OSFED and UFED. OSFED included atypical AN (OSFED-AN) subthreshold BN (OSFED-BN) and subthreshold BED (OSFED-BED), as well as purging disorder (OSFED-PD) and night eating syndrome (OSFED-NES). No studies reporting ARFID, rumination disorder or Pica were identified.Table 1Overview of included studies published 2012-2017. Studies are grouped by design and listed in chronological orderAuthor (Year)NCountryGender\
(N or %)Age range Mean (*SD*)SampleAssessmentPrevalence typePrevalence (%) of\
ED, AN, BN (95% CI)Prevalence (%) of\
BED, OSFED, UFED (95% CI)2-STAGE DESIGN Mustelin et al. \[[@CR10]\]^a^2825Finland♀22-27\
24.4 (0.9)FinnTwin16 sample*Screening:* Self-report questionnaire developed for the study and three subscales from the EDI-2\
*Diagnosis:* SCID-I/NPLifetimeNROSFED + UFED: 1.5 (1.1-2.1)\
OSFED: 0.6 (0.3-1.0)\
UFED: 0.9 (0.6-1-4) Mustelin et al. \[[@CR7]\]^b^2825Finland♀22-27\
24.4 (0.9)FinnTwin16 sample*Screening:* Self-report questionnaire developed for the study and three subscales from the EDI-2\
*Diagnosis:* SCID-I/NPLifetimeAN: 3.6 (2.7-4.2)NR Solmi et al. \[[@CR16]\]^c^1698UK♀ (66%)\
♂ (44%)16-90\
(mean and SD not available)SELCoH*Screening:* SCOFF\
*Diagnosis:* SCID-I-N/PPointED: 7.4 (4.1-)13.0\
AN: 0.0 (0)\
BN: 0.8 (0.4-1.9)BED: 3.6 (1.4-9.0)\
OSFED: 2.4 (0.9-6.7)\
OSFED-PD: 0.6 (0.2-1.5%) Smink et al. \[[@CR15]\]^d^1597Holland♀ (53.9%)\
♂ (56.1%)19.1 (0.6)\
(age range not available)Community cohort*Screening*: Questionnaire on mental health and social functioning, height/weight and WHO-CIDI\
*Diagnosis*: SCID-I and parts of EDELifetime (L)\
Point (P)♀\
ED (L, P): 5.7, 3.7 (4.2-7.5, 2.6-5.2)\
AN (L, P): 1.7, 1.2 (1.0-2.9, 0.6-2.1)\
BN (L, P): 0.8, 0.6 (0.3-1.7, 0.2-1.3)\
♂\
ED (L, P): 1.2, 0.5 (0.6-2.3, 0.1-1.4)\
AN (L, P): 0.1, 0.1 (0.0-0.8, 0.0-0.8)\
BN (L, P): 0.1, 0.1 (0.0-0.8, 0.0-0.8)♀\
BED (L, P): 2.3, 1.6 (1.4-3.6, 0.9-2.7)\
OSFED (L, P): 0.6, 0.3 (0.2-1.3, 0.1-1.0)\
UFED (L, P): 0.2, 0.0 (0.0-0.8, 0)\
♂\
BED (L, P): 0.7, 0.3 (0.2-1.6, 0.0-1-0)\
OSFED (L, P): 0.3, 0.0 (0.0-1.0, 0)\
UFED (L, P): 0.0, 0.0 (0,0) Machado et al. \[[@CR9]\]3048Portugal♀12-23\
16.2 (1.3)\
18-58\
21.8 (4.3)Female high-school and university students*Screening*: EDE-Q\
*Diagnosis*: EDEPointED: 3.87 (CI NR)\
AN: 0.69 (CI NR)\
BN: 0.59 (CI NR)BED: 0.62 (CI NR)\
EDNOS: 1.97 (CI NR)INTERVIEW Mohler-Kuo et al. \[[@CR4]\]^e^10,038Switzerland♀ (56%)\
♂ (44%)15-60\
(mean and SD not available)Household surveyWHO-CIDILifetime (L)\
12-month (12-m)♀AN (L, 12-m): 1.9, 0.07 (1.6-2-3, 0.03-0.2)\
AN ♂ (L, 12-m): 0.2, 0.03 (0.1-0.4, 0.004-0.2)NR Hay et al. \[[@CR11]\]^f^6041Australia♀ (−)\
♂ (−)15-96\
(mean and SD not available)Cross sectional population sample.Items based on diagnostic items from the EDEPoint (3-month)Total sample (% females):\
ED: 16.3 (15.4-17.3)\
AN: 0.46 (83%) (0.32-0.67)\
BN: 0.66 (69%) (0.49-0.9)Total sample (% females):\
BED: 5.58 (57%) (5.03-6.19)\
OSFED-BN: 0.70 (74%) (0.51-0.94)\
OSFED-BED: 6.92 (55%) (6.31-7.59)\
OSFED-PD: 0.58 (77%) (0.42-0.80)\
UFED: 1.41 (73%) (1.14-1.74) Munn-Chernoff et al. \[[@CR26]\]^g^3230\
1790^MZ^\
1440^DZ^USA♀18-29\
Median: 22\
(mean and SD not available)Population-based twin studyAdapted version of SSAGALifetimeAN: 1.37 (1.00-1.84)OSFED-PD: 3.77 (3.14-4.49) Fairweather-Smith & Wade \[[@CR19]\]^h^699Australia♀12.7-19.8 (across 3 waves)\
(age range not available)Adolescent female twin pairsEDECalculated a total prevalence rate based on wave 1-3ED: 10.4 (8.3-12.9)\
AN: 2.0 (CI NR)\
BN: 1.0 (CI NR)BED: 2.4 (CI NR)\
OSFED: 5.0 (CI NR)\
OSFED-AN:1.9 (CI NR)\
OSFED-BN:2.6 (CI NR)\
OSFED-PD: 0.6 (CI NR) Stice et al. \[[@CR17]\]^i^496USA♀Baseline:\
12-15\
Mean = 13\
(SD not available)Community sampleEDDILifetime (L)AN: 0.8 (± 0.6)\
BN: 2.6 (± 1.4)BED: 3.0 (± 1.3)\
OSFED: 11.5 (± 2.8)\
OSFED-AN: 2.8 (±1.5)\
OSFED-BN: 4.4 (±1.6)\
OSFED-BED: 3.6 (± 1.5)\
OSFED-PD: 3.4 (± 1.6) Hudson et al. \[[@CR18]\]^j^888USA♀ (66.4%)\
♂ (33.6%)18-70\
46.7 (17.4)First-degree relatives of probands with or without BEDSCIDLifetime (L)\
Point (P)NR♀ BED (L, P): 3.6, 1,7 (CI NR)\
♂ BED (L, P): 2.1, 0.8 (CI NR)SELF-REPORT Cossrow et al. \[[@CR27]\]^k^22,397USA♀ (54.4%)\
♂ (45.6%)≥18\
51.1(15.8)\
(age range not available)NHWS sampleQuestions assessing BED criteria through a self-administered Internet surveyLifetime (L)\
3-month (3-m)\
12-month (12-m)NRBED ♀ + ♂ (L, 3-m, 12-m):\
2.03, 1.19, 1.64 (1.83-2.26, 1.04-1.37, 1.45-1.85)\
BED ♀: (L, 3-m, 12-m):\
2,61, 1,60, 2.00 (2.34-2.92, 1.38-1.85, 1.76-2.28)\
BED ♂: (L, 3-m, 12-m):\
1.41, 0,76, 1,24 (1.13-1.77, 0.56-1.03, 0.97-1.59) Hammerle et al. \[[@CR36]\]^l^1654Germany♀ (*N* = 873)\
♂ (*N* = 781)13.4 (0.8)\
(age range not available)National school-based cross-sectional surveySIAB-S (as questionnaire) and EDI-2Point*Full syndrome* (sex ratio female-male)AN: 0.3 (5:0) (0.1-0.7)\
BN: 0.4 (5:1) (0.2-0.8)BED: 0.5 (5:3) (0.2-0.9)\
OSFED-AN: 3.6 (45:13) (2.7-4-5)\
OSFED-BN:0.0 (−) (0,-)\
OSFED-BED: 0.0 (−) (0,-)\
OSFED-PD: 1.9 (22:9) (1.3-2.77) Flament et al. \[[@CR14]\]^m^3043Canada♀ (*N* = 41.2%)\
♂ (*N* = 58.8%)11-21\
14.2 (1.6)Community sampleEDDSPointED (♀, ♂): 4.46, 2.21 (4.4-4.5, 1.5-3.2)\
AN (♀, ♂): 0.06, 0.0 (0.00-0.31, 0)\
BN (♀, ♂): 2.01, 1.31 (1.23-3.25, 0.80-2.13)BED (♀, ♂): 0.68, 0.16 (0.27-1.71, 0.04-0.65)\
OSFED-PD (♀, ♂): 1.51, 0.74 (0.89-2.53, 0.38-1.41) Flament et al. \[[@CR13]\]^n^3022Canada♀ (*N* = 1789)\
♂ (*N* = 1233)11-20\
14.2 (1.6)Community sampleEDDSPointED (♀ + ♂): 3.7 (2.8-4.7)\
AN (♀ + ♂): 0.1 (0.0-0.1)\
BN (♀ + ♂): 1.6 (1.61.1-2.5)BED (♀ + ♂): 0.5 (0.2-1.2)\
OSFED-PD (♀ + ♂): 1.4 (1.0-1.9) de Zwaan et al. \[[@CR21]\]^o^2460Germany♀ (51.1%)\
♂ (48.9%)14-85\
48.1 (19.0)Population sampleNEQ and EDE-Q8PointNROSFED-NES: 1.1 (CI NR) Runfola et al. \[[@CR22]\]1636USA♀ (59.5%)\
♂ (40.5%)18-26\
20.9 (1.7)University studentsAn online survey using the NEQPointNROSFED-NES: 4.2 (CI NR) Allen et al. \[[@CR20]\]^p^1383Australia♀ (49%)\
♂ (51%)14-20\
14-years:\
14.0 (0.2)\
17-years:\
16.9 (0.2)\
20-years:\
20.0 (0.4)Prospective, population-based cohort studyItems adapted from the ChEDE and the EDE-QPointED (♀, ♂)\
14-yrs: 8.5, 1.2\
17-yrs: 15.2, 2.6\
20-yrs: 15.2, 2.9\
AN (♀, ♂)\
14-yrs: 0.3, 0.0\
17-yrs: 1.4, 0.0\
20-yrs: 0.6, 0.0\
BN (♀, ♂)\
14-yrs: 2.7, 0.4\
17-yrs: 8.7, 0.7\
20-yrs: 7.9, 1.6BED (♀, ♂)\
14-yrs: 1.8, 0.0\
17-yrs: 1.4, 1.2\
20-yrs: 4.1, 0.7\
OSFED (♀, ♂)\
14-yrs: 3.6, 0.7\
17-yrs: 4.1, 0.9\
20-yrs: 2.7, 0.6\
OSFED-PD (♀, ♂)\
14-yrs: 2.7, 0.4\
17-yrs: 2.1, 0.6\
20-yrs: 1.6, 0.3\
OSFED-AN (♀, ♂)\
14-yrs: 0.9, 0.3\
17-yrs: 0.0, 0.0\
20-yrs: 0.1, 0.3OTHER Trace et al. \[[@CR6]\]^q^13,295Sweden♀20-47\
(mean and SD not available)Twin registry subsampleAn expanded SCID based instrumentLifetimeBN: 1.6 (CI NR)BED 0.4 (CI NR)*Note.* Prevalence rates are presented exactly as reported in their respective studies. ♀ = Females; ♂ = MalesAbbreviations: *95% CI* 95% Confidence Interval, *NR* Not Reported, *ED* Eating Disorders, *AN* Anorexia Nervosa, *ARFID* Avoidant Restrictive Food Intake Disorder, *BN* Bulimia Nervosa, *BED* Binge Eating Disorder, *OSFED* Other Specified Feeding and Eating Disorders, *UFED* Unspecified Feeding and Eating Disorders, *L* Lifetime prevalence, *P* Point prevalence, *12-m* 12-month prevalence, *3-m* 3-month prevalence^a^ = Prevalence rates are based on the same sample as in Mustelin et al. \[[@CR7]\]^b^. Reported prevalence rates are based on observed cases. Finn Twin16 is a nationwide population based cohort. SCID I-N/P = Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-Patient Edition \[[@CR37]\]; EDI-2 = Eating Disorder Inventory-2 \[[@CR38]\]^b^ = Prevalence rates are based on the same sample as in Mustelin et al. \[[@CR10]\]^a^. AN diagnoses were first assessed using DSM-IV, then retrospectively recoded using DSM-5 criteria^c^ = SELCoH = South East London Community Health Study. SCOFF = Sick, Control, One stone, Fat, Food Questionnaire \[[@CR39]\]^c^ = SCID-I = Structured Clinical Interview for DSM-IV Axis I Disorders^d^ = WHO-CIDI = World Health Organization Composite International Diagnostic Interview \[[@CR40]\]^e^ = EDE = the Eating Disorder Examination \[[@CR41]\]^g^ = MZ = Monozygotic twins; DZ = Dizygotic twins; SSAGA = An adaptation of the Semi-Structured Assessment on the Genetics of Alcoholism \[[@CR42]\];^h^ = CI was not reported (NR) for separate ED diagnoses^i^ = EDDI = The Eating Disorder Diagnostic Interview \[[@CR43]\]; The diagnostic category "Feeding or eating disorder not elsewhere classified (FEDNEC)" was renamed by the authors of the current review, to OSFED^j^ = BED diagnoses were first assessed using DSM-IV, then retrospectively recoded using DSM-5 criteria. CI was not reported (NR) for any ED diagnoses^k^ = NHWS = the National Health and Wellness Survey^l^ = SIAB-S = the Structured Interview for Anorexia and Bulimia Nervosa Self-report \[[@CR44]\]; OSFED-AN = Atypical AN (all criteria is med except significantly low weight), OSFED-BN = Subthreshold BN (of low frequency and/or limited duration), OSFED-BED = Subthreshold BED (of low frequency and/or limited duration), OSFED-PD = Purging Disorder (Recurrent purging in the absence of binge eating)^m^ = EDDS = the Eating Disorder Diagnostic Scale \[[@CR45]\]. NB: Prevalence rates originate from the Flament et al. \[[@CR14]\]^m^ study where overall (♀ + ♂) ED rates are reported^n^ = Prevalence rates based on the same sample, stratified by gender are presented in Flament et al. \[[@CR14]\]^no^ = NEQ = Night Eating Questionnaire \[[@CR23]\]; EDE-Q8 = The Eating Disorder Examination Questionnaire 8 \[[@CR24]\]^p^ = ChEDE = the Child Eating Disorder Examination \[[@CR46]\]. Confidence intervals were reported visually (using error bars) in the study, but were not presented clearly enough to exclude risk of misinterpretation, and were therefore not included in the table^q^ = Prevalence rates reported represent binge eating frequency per month ≥4 times

The majority of included studies presented data from US samples (*N* = 5), closely followed by Australia (*N* = 3), Germany (*N* = 2), Finland (N = 2) and Canada (N = 2). Portugal, Sweden, United Kingdom, Switzerland and the Netherlands all represented one individual study. Ages ranged from 11 to 96, with eight studies reporting data from adults only (\>18), nine studies reporting rates from mixed age samples (i.e. children, adolescents *and* adults) and two studies presented data collected in samples below the age of 15. Sample sizes ranged from 496 to 22,397, and approximately 25% (*N* = 5) of the included studies followed a two-stage design approach in estimating ED prevalence. Six studies used interviews alone to establish ED diagnoses, and seven studies employed self-reports. Trace et al. \[[@CR6]\] did not specify the design of the study. Disregarding prevalence reports using data from overlapping samples \[[@CR7], [@CR10], [@CR13], [@CR14]\], all studies employing 2-stage designs had used different screening instruments.

Prevalence rates {#Sec10}
----------------

In 2-stage design studies, lifetime AN prevalence rates in females ranged from 1.7% \[[@CR15]\] to 3.6% \[[@CR9]\], and point prevalence ranged from 0.67% \[[@CR9]\] to 1.2% \[[@CR15]\]. Only one study reported male AN prevalence and they found both point and lifetime to be 0.1% \[[@CR15]\]. BN was most commonly assessed using point prevalence, but was only assessed in two out the five 2-stage design studies \[[@CR9], [@CR15]\]. These studies reported nearly identical point BN prevalence rates of 0.59% and 0.6% respectively in females. Point prevalence rates for BED were reported in three studies, and ranged from 0.62% \[[@CR9]\] (females only) to 3.6% \[[@CR16]\] (males and females combined). Lifetime prevalence rates for OSFED ranged from 0.3% in males \[[@CR15]\] to 0.6% in females \[[@CR10]\] and point prevalence from 0.0% in males \[[@CR15]\] to 2.4% in a sample combining male and females rates. Lifetime prevalence rates of UFED in females were 0.2% \[[@CR15]\] and 0.9% \[[@CR10]\] respectively.

In interview based studies, lifetime prevalence of AN in females ranged from 0.8% \[[@CR17]\] to 1.9% \[[@CR4]\]. Lifetime BN prevalence in females of was only reported in one of these studies, with a rate of 2.6% \[[@CR17]\]. In two out of the six interview-based studies, lifetime rates of BED were reported. BED in females were 3.0% \[[@CR17]\] and 3.6% \[[@CR18]\] respectively, whereas the corresponding rates for males were only assessed in one study \[[@CR18]\] reporting a rate of 2.1%. In females prevalence of OSFED was reported in the interview based prevalence studies, with overall OSFED point prevalence rates ranging from 5% \[[@CR19]\] to lifetime prevalence rate of 11% \[[@CR17]\].

Point prevalence was most commonly reported in studies using the self-report design. Here, AN rates ranged from 0.06% \[[@CR14]\] to 1.2% in females \[[@CR15]\]. BN prevalence rates ranged from 0.45% \[[@CR11]\] to 8.7% in females \[[@CR20]\]. BED rates ranged from 0.0% (in males) \[[@CR20]\] to 4.1% (in females). Two studies \[[@CR21], [@CR22]\] set out to investigate the occurrence of night eating syndrome (NES). In these studies, point prevalence was established using the Night Eating Questionnaire (NEQ) \[[@CR23]\] and a brief version of the Eating Disorder Examination Questionnaire, the EDE-Q8 \[[@CR24]\]. Rates reported for both genders were 1.1% and 4.2% respectively.

Discussion {#Sec11}
==========

The current study reviewed the prevalence of DSM-5 eating disorders. A total of 19 studies were identified in our literature search, with results showing substantial variability in prevalence rates. A wide range of both point- and lifetime prevalence rates were reported across included studies, with variance being dependent on, first and foremost, the methodologies applied.

As intended, a number of studies now support the decline in EDNOS/OSFED prevalence following the DSM-5 diagnostic revision intention \[[@CR10], [@CR11]\]. Decreased EDNOS/OSFED prevalence has also been reported in studies having recoded ED diagnoses \[[@CR9], [@CR13], [@CR20]\]. However, although the introduction of the new DSM-5 criteria appears to have resolved some of the challenges associated with EDNOS, OSFED still represents a heterogeneous group in the DSM-5, including a variety of different ED conditions. For example, PD, which has been shown to be associated with significant medical complications \[[@CR25]\], was investigated specifically in three studies in our review \[[@CR11], [@CR14], [@CR26]\]. Prevalence rates ranged from 0.58% (CI 0.42-0.80) -- 3.77% (CI 3.14-4.49) with results illustrating a trend towards higher rates in females compared to males, as well as higher rates in adults compared to adolescents. However, it should be noted that lifetime prevalence rates as opposed to point prevalence rates, in general, is expected to be higher, especially when assessed in older populations. Night eating syndrome (NES) was also included in the DSM-5 OSFED category, and specifically assessed in two of the reviewed studies. \[[@CR21], [@CR22]\] Both adopted the self-report measure Night Eating Questionnaire (NEQ) \[[@CR23]\]. Whereas de Zwaan and colleagues \[23\] reported a point prevalence of 1.1% among males and females aged 14-85 years (mean age 48), Runfola et al. \[24\] reported a prevalence of 4.2 among males and females aged 18-26 years (mean age 21). These discrepant findings in prevalence may relate to the differences in age between the two samples, but more research is warranted to investigate this further. Additionally, the new category Unspecified Feeding or Eating Disorder (UFED) was introduced in the DSM-5. UFED is used to describe symptoms characteristic of feeding or eating disorders causing significant stress or impairments in functioning, but without meeting full criteria for an ED diagnosis. The UFED category can be used when reasons for not meeting full criteria is lacking or not further specified by clinicians. Three of the included studies \[[@CR10], [@CR11], [@CR15]\] reported prevalence of UFED, with rates ranging from 0.0% to 1.41%. Further research is needed to yield more information about the prevalence of PD, NES, and UFED.

After being included as an EDNOS in DSM-IV, BED was introduced as a specified and independent diagnostic category in DSM-5. Prevalence of BED was reported in several studies included in this review, and the prevalence of BED generally increased by increasing age in the reviewed studies. For example, Allen et al. \[[@CR20]\] assessed BED among 1383 young Australian males and females at ages 14, 17, and 20. Point prevalence increased from 1.8% to 4.1% from age 14 to 20 (increase from 0.0% to 0.7% in males). Similarly, Stice et al. \[[@CR17]\] investigated 496 young females (mean age 13 years at baseline), and reported a cumulative incidence of 2.7% and a lifetime prevalence at 3.0% by age 20. Finally, Trace et al. \[[@CR6]\] assessed a larger and older sample of 13,295 females aged 20-47 years, with a reported lifetime prevalence of 5.8%. Prevalence of BED was generally higher among females than males across studies. A potential explanation for variability in BED prevalence rates is the inconsistent or lack of use of the DSM-5 marked distress criterion and binge eating specifiers such as guilt after binge eating \[[@CR11]\].

Impact of the DSM-5 on prevalence estimates {#Sec12}
-------------------------------------------

It is of interest to review whether the transition from DSM-IV to DSM-5 has yielded the intended alterations in reported prevalence, i.e. increased prevalence of AN and BN, and decreased prevalence of the residual category EDNOS/OSFED. Several of the included studies in the present review have estimated prevalence of EDs as defined by both DSM-IV and DSM-5 in the same sample. Such recoding of diagnostic categories according to DSM-IV versus DSM-5 informs us on the impact of the DSM-5 on different ED prevalence rates. One study \[[@CR7]\] assessed prevalence of AN by first adopting DSM-IV criteria. Subsequent to recoding according to the DSM-5 criteria, the authors observed a 60% increase in lifetime prevalence of AN among the 2825 female participants (mean age 24 years), from 2.2 to 3.6%. Another study recoding from DSM-IV to DSM-5 diagnoses investigated 1383 males (49%) and females at ages 14, 17, and 20 \[[@CR20]\]. Significantly greater ED prevalence rates were reported when using DSM-5 criteria at all ages for females, and at age 17 only for males. These findings are in line with the study of Flament et al. \[[@CR13]\] reporting that prevalence of full-threshold EDs increased from 1.8 to 3.7% after recoding from DSM-IV to DSM-5 criteria. Decreased prevalence of the residual ED categories (EDNOS/OSFED) when adopting DSM-5 criteria have also been reported across studies having recoded ED diagnoses \[[@CR9], [@CR13], [@CR20]\]. It is worth noting that although research recoding ED prevalence from DSM-IV to DSM-5 has been important in the initial evaluation of the proposed DSM-5 criteria, these studies may have missed patients who initially did not qualify for an ED diagnoses based on DSM-IV, but who would have met criteria for a DSM-5 ED. This may imply a risk of inaccurate prevalence estimates in these studies.

A main intention of the DSM-IV revisions was to minimize the use of catch-all diagnoses such as Eating Disorders Not Otherwise Specified (EDNOS), the most frequently, reported ED diagnosis in the DSM-IV. However, the revisions made may not only contribute to altered rates of AN, BN and OSFED diagnoses, but may also increase the likelihood of reaching the threshold for a formal ED diagnosis. As the new OSFED category includes disorders which lack strict diagnostic criteria (e.g. PD and NES which lacks frequency criteria), clinicians and researchers should be vigilant with regards to the characteristics, especially significant distress and impairments, separating eating *disturbances* from eating *disorders.*

Methodological aspects {#Sec13}
----------------------

Methodological aspects are likely to influence both lifetime- and point prevalence rates including assessment measures adopted and samples investigated \[[@CR3]\]. The majority of studies in this review adopted self-report to assign ED diagnoses, followed by interviews and 2-stage designs. Although self-report assessments have its obvious advantages in terms of being cost- and time effective, only diagnostic interviews can help determine the presence (or absence) of a formal ED diagnosis as defined by the DSM. Methodological issues such as these should be considered when interpreting prevalence rates across studies. In addition to assessment measure per se, recruitment strategy and design are important aspects to consider when evaluating quality of studies and consequently reliability of results. The 2-stage design, including stage one with screening followed by stage two with clinical diagnostic interview, have been considered the preferred approach to estimate prevalence rates. In the current study, aiming to review the prevalence of diagnosable EDs as defined by the diagnostic manual DSM-5, it may therefore be timely to consider the included 2-stage design studies \[[@CR7], [@CR9], [@CR10], [@CR15], [@CR16]\] to be among the highest ranked studies in terms of quality. However, another marker of quality in epidemiological studies is sample size. The reviewed studies with the largest sample sizes include samples of *N* = 6041 \[[@CR11]\], 13,295 \[[@CR6]\], 10,038 \[[@CR4]\], and 22,397 \[[@CR27]\]. It is worth noting that none of these latter studies are among the mentioned 2-stage design studies, demonstrating the necessity to consider multiple methodological aspects when evaluating quality. In addition to the above-mentioned aspects, sample characteristics are likely to influence reported prevalence rates, and includes both age ranges and gender distributions. One of the intentions of the DSM-5 was to better capture EDs in males than during the DSM-IV era, and was a central rationale for removing the amenorrhea criteria for AN. However, as the DSM-5 revisions have contributed to higher prevalence of full-threshold AN and BN in general, it is difficult to detect whether the DSM-5 has led to better detection of male EDs per se. Also, although the amenorrhea criterion has been removed, the core ED psychopathology outlined in the DSM-5 is still biased towards females as it focuses on drive for thinness rather than muscularity. Furthermore, assessment measures used to detect ED psychopathology are often gender biased in that they have been developed to capture "female" psychopathology and symptoms, and also, as they most commonly are validated using female samples \[[@CR28], [@CR29]\]. Issues such as these may complicate the detection and description of ED pathology in males. Another methodological issue subsequent to the introduction of DSM-5 is the removal of a specific weight threshold for AN. This has clear advantages, maybe in particular in terms of individual and flexible evaluations in clinical settings, but it is worth noting that in research, the lack of an explicit weight criterion may lead to larger weight variations compared to earlier. In general, it is important to strive for consistent use of DSM-5 categories, which will aid the interpretation of prevalence rates across studies.

New diagnostic categories in the DSM-5 include ARFID (problem with eating not related to weight or shape concerns, leading to inability to take in adequate nutrition), pica (recurrent consumption of "nonnutritive, nonfood" items), and rumination disorder (RD; i.e. recurrent, effortless regurgitation of food). Although none of the included studies investigated these full-threshold diagnoses, three studies which were excluded due to their sub-threshold nature, addressed features of ARFID \[[@CR30]\], pica and RD \[[@CR31]\], reporting frequency numbers ranging from 0 to 3.2%. More research is needed to determine the prevalence of these diagnostic categories.

Finally, this review reports the prevalence of eating disorders according DSM-5 criteria. In a historical perspective there have been important changes to the diagnostic criteria since AN and BN were introduced in the DSM-III \[[@CR32]\] in 1980. For example, in the DSM-III, the weight loss criteria for AN was "*25% below original body weight*", which was then revised to "*body weight less than 85% of that expected*" in the DSM-IV \[[@CR1]\], and subsequently, redefined in the DSM-5 \[[@CR2]\] to "*significantly low body weight*". For BN there were no criteria for frequency of binge eating and compensatory behavior in the DSM-III. With the DSM-III-R update, the frequency was specified to twice a week, and in DSM-5, it was reduced to once a week. These revisions will greatly influence prevalence rates in the years to come, and are crucial to address when comparing DSM-5 based prevalence to earlier epidemiological studies in EDs.

Strengths and limitations {#Sec14}
-------------------------

This is the first systematic review of DSM-5 prevalence studies in EDs, and offers the reader an early snapshot of the extant prevalence literature. The core strength of the study is the thoroughness of the systematic literature review, and the detailed screening process conducted by two of the authors. Conversely, only one database was used to search the literature and only articles that were written in English (or had an available published English translation) were reviewed representing a limitation of the current study. Further, a meta-analysis was not performed which also represents a potential weakness. In addition, our search date (February 2017) dates our paper. In this interim, three publications relevant to the scope of our paper have been published. Hay et al. \[[@CR33]\] investigated the prevalence and burden of ARFID and other DSM-5 EDs in an Australian population, Ernst et al. \[[@CR34]\] explored how the DSM-5 revisions affected the prevalence, sex ratio and diagnostic distribution of EDNOS/OSFED in a student sample, and Micali et al. \[[@CR35]\] investigated lifetime and 12-month prevalence of EDs amongst women in mid-life. Their relevance to the extant literature warrant a more detailed account in future epidemiological ED studies.

Conclusions {#Sec15}
===========

In conclusion, prevalence rates varied significantly across the 19 studies reviewed, much likely due to variations in study design, diagnostic assessment routines, samples sizes and characteristics. None of the included studies investigated the prevalence of the DSM-5 feeding disorders pica, ARFID and RD, warranting further investigation in future epidemiological studies. As our review is limited by a small number of studies published during a limited time frame, and in addition, fails to capture the full range of DSM-5 diagnoses, reported trends should be interpreted with caution.
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:   Anorexia nervosa
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:   Avoidant restrictive food intake disorder
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:   Binge eating disorder
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:   Bulimia nervosa
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:   Confidence interval

DSM-5

:   Diagnostic and statistical manual of mental disorders, fifth edition

DSM-IV

:   Diagnostic and statistical manual of mental disorders, fourth edition

ED

:   Eating disorder

EDE

:   Eating disorder examination

EDI-2

:   Eating disorder inventory

EDNOS

:   Eating disorder not otherwise specified

L

:   Lifetime

NEQ

:   Night eating questionnaire

NES

:   Night eating syndrome

NR

:   Not reported

OSFED

:   Other specified feeding and eating disorders

P

:   Point

PD

:   Purging disorder

SCID I-N/P

:   Structured clinical interview for DSM-IV-TR axis I disorders, research version, non-patient edition
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:   Structured clinical interview for DSM-IV axis I disorders
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:   Sick, control, one stone, fat, food questionnaire

SELCoH

:   South East London Community Health Study

UFED

:   Unspecified feeding and eating disorder

WHO-CIDI

:   World Health Organization Composite International Diagnostic Interview
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